Testosterone Cypionate
Brand names: Depo-Testosterone, Testosterone Cypionate
At a glance
- Medicare prescriptions, 2024
- 832,382
- Medicare drug cost
- $30.2M
- Average cost per prescription
- $36.30
- Clinicians who prescribed it
- 28,945
Where it is prescribed
List the prescribers in any state, county, city or ZIP code →
What it is used for
DEPO-Testosterone Injection is indicated for replacement therapy in the male in conditions associated with symptoms of deficiency or absence of endogenous testosterone. 1. Primary hypogonadism (congenital or acquired)-testicular failure due to cryptorchidism, bilateral torsion, orchitis, vanishing testis syndrome; or orchidectomy. 2. Hypogonadotropic hypogonadism (congenital or acquired) - gonadotropin or LHRH deficiency, or pituitary-hypothalamic injury from tumors, trauma, or radiation. Safety and efficacy of DEPO-Testosterone (testosterone cypionate) in men with “age-related hypogonadism” (also referred to as “late-onset hypogonadism”) have not been established.
From the FDA-approved prescribing information (label dated August 2026). Full labels on DailyMed (opens in a new tab)
Who prescribes it
- Family Medicine 27.3%
- Urology 18.5%
- Internal Medicine 15.9%
- Nurse Practitioners 14.9%
- Endocrinology & Diabetes 9.9%
- Physician Assistants 8.7%
- General Practice 1.1%
- Infectious Disease 0.5%
- OB-GYN (Obstetrics & Gynecology) 0.5%
- Cardiology 0.3%
- Geriatric Medicine 0.2%
- Pain Medicine 0.2%
All prescribers, by place, name or specialty →
Share of Medicare prescriptions written by each specialty. Select one to list its prescribers.
Trend, 2019–2024
Medicare prescriptions rose 49% from 2019 to 2024.
Biggest change by state since 2019
- Arkansas +111%
- Louisiana +87%
- Wisconsin +83%
- Oklahoma +78%
- Alabama +75%
- Washington (smallest change) +26%
- Massachusetts (smallest change) +28%
From CMS’s yearly state and national Part D summaries, which count every prescriber, including those CMS leaves out of its per-clinician data (fewer than 11 prescriptions). That is why these totals are higher than the count at the top of this page. Prescriptions include refills.
What it looks like
Pills from 1 maker on file. The same medicine can look different depending on who made it, so check the imprint (the letters and numbers on the pill) with your pharmacist if a refill looks different.
Remedyrepack Inc.
| Strength | Looks like | Imprint |
|---|---|---|
| 200 mg | white injection | |
Source: DailyMed (U.S. National Library of Medicine), from each maker’s FDA drug listing. A few makers are shown, not every one. Never take a pill you can’t identify; ask a pharmacist.
Industry payments about this drug
Drug makers reported $37,446 in payments to clinicians that named this drug in 2025 (meals, speaking, consulting and similar).
- Azurity Pharmaceuticals, Inc. $30,046
- Pfizer Inc. $7,400
Source: CMS Open Payments, general payments (not research), program year 2025. A payment is not evidence of wrongdoing. Payments by doctor
Recalls and shortages
Not on the FDA drug shortage list.
8 recalls since 2020
- Apr 2025 · Eugia US LLC · Class II
cGMP: complaints of crystals not redissolving into solution after warming and shaking the vials. - Feb 2023 · Azurity Pharmaceuticals, Inc. · Class II
cGMP: complaints of crystals not redissolving into solution after warming and shaking the vials. - Jun 2022 · Sun Pharmaceutical Industries Inc · Class II
cGMP - Water leakage - Jun 2022 · Sun Pharmaceutical Industries Inc · Class II
Lack of Assurance of Sterility: Manufacturing deviation which was reported due to a microbial excursion - Jun 2022 · Sun Pharmaceutical Industries Inc · Class II
CGMP Deviations: Manufacturing deviations were reported due to an abnormal appearance on parts of machinery. - Jun 2022 · Sun Pharmaceutical Industries Inc · Class II
CGMP Deviations: lots made with same active pharmaceutical ingredient (API) as lots that were rejected due to manufacturing issues that could cause the product to be out of specification for impurities. - Jan 2021 · Sun Pharmaceutical Industries Inc · Class III
Incorrect Labeling: Incorrect lot number on secondary packaging - Jan 2020 · Sun Pharmaceutical Industries, Inc. · Class II
cGMP Deviations; released lots were manufactured under similar manufacturing conditions to a previously rejected OOS Lot.
Recalls usually affect specific lots from one maker, not every version of a drug. Class I is the most serious; most drug recalls are Class II. FDA recalls (opens in a new tab)
Sources: CMS Medicare Part D Prescribers by Provider and Drug (2024; prescriptions include refills, and CMS hides counts under 11 per prescriber); U.S. Food and Drug Administration, openFDA (drug labels, NDC directory, enforcement reports, drug shortages); CMS Open Payments 2025; ClinicalTrials.gov. General information only, not medical advice; not yet reviewed by our medical reviewer.